For infusion centers, specialty practices, and reimbursement teams
Medicare allows $31.479 per 10 mg unit
400 mg Remicade = 40 units = $1,259.16 drug allowed
J1745 · infliximab · Q3 2026 Medicare Part B
Calculate reimbursement ↓Medicare reimbursement
Drug allowed amount · J1745 × 40 units · 40 × $31.479 = $1,259.16
Add administration
| Claim line | Units | Allowed |
|---|---|---|
| J1745 | 40 | $1,259.16 |
| 96413 | 1 | $133.27 |
| 96415 | 1 | $28.39 |
| Total allowed | $1,420.82 |
CMS ASP · Q3 2026 · Medicare Physician Fee Schedule · 2026 · national non-facility amounts
Medicare provides a public benchmark. Commercial plans can reimburse the same Remicade infusion at a different allowed amount.
Choose a payer to see which states have pricing on file.
Remicade · 400 mg
| Payer | Pricing available |
|---|---|
| Aetna | ✓ Available |
| UnitedHealthcare | ✓ Available |
| Cigna | ✓ Available |
| Anthem / Elevance | ✓ Available |
| Regence | ✓ Available |
| Premera | ✓ Available |
| Kaiser | ✓ Available |
| + more payer price-file sets | ✓ |
Knowing what the payer allows is only part of the estimate.
CareCost uses the same reimbursement data to build the patient estimate.
Calculate patient responsibility →For Q3 2026, Medicare Part B allows $31.479 per 10 mg unit. Remicade billing code: J1745.
| Dose | Units | Medicare drug allowed |
|---|---|---|
| 100 mg | 10 | $314.79 |
| 200 mg | 20 | $629.58 |
| 300 mg | 30 | $944.37 |
| 400 mg | 40 | $1,259.16 |
| 500 mg | 50 | $1,573.95 |
| 600 mg | 60 | $1,888.74 |
| 800 mg | 80 | $2,518.32 |
| 1,000 mg | 100 | $3,147.90 |
A commercial payer's J1745 rate is negotiated, not ASP+6% — it should never be assumed to equal the Medicare payment limit above. Full explanation: How commercial drug reimbursement works →
Drug: J1745 — infliximab, 10 mg
Infusion: 96413 — chemotherapy administration, initial hour · 96415 — each additional hour
Some payer or billing circumstances may use different administration coding.
| Product | HCPCS | Medicare rate / 10 mg | 400 mg |
|---|---|---|---|
| Remicade | J1745 | $31.479 | $1,259.16 |
| Inflectra | Q5103 | $27.71 | $1,108.40 |
| Renflexis | Q5104 | $26.615 | $1,064.60 |
| Avsola | Q5121 | $30.83 | $1,233.20 |
Under Q3 2026 Medicare Part B, J1745 has a payment limit of $31.479 per 10 mg unit. Commercial reimbursement varies by payer and provider contract.
400 mg equals 40 J1745 billing units. 40 × $31.479 = $1,259.16 for the drug before administration reimbursement.
Select the payer, state, and dose. CareCost uses payer-published pricing data to identify applicable reimbursement rates. Check a payer →
No. J1745 pairs with two separate administration lines — 96413 (initial hour) and 96415 (each additional hour). Full explanation: why administration is billed separately →
Compare J1745's expected allowed reimbursement above against your acquisition and administration costs. Calculate the reimbursement spread →
Data current: Medicare pricing Q3 2026 · commercial price files Q2 2026
Every CareCost reimbursement result links back to the underlying pricing source. Last reviewed: .
CareCost